1. Introduction {#sec1}
===============

Autosomal dominant lateral temporal epilepsy (ADLTE; OMIM 600512), also named autosomal dominant partial epilepsy with auditory features (ADPEAF), is a familial focal epilepsy syndrome characterized by ictal auditory auras or aphasia \[[@B1]--[@B3]\]. Seizure onset usually occur in the first two decades of life, secondarily generalized tonic-clonic seizures manifest in most patients, and interictal EEGs show mild temporal anomalies in a minority of patients \[[@B3], [@B4]\]. Familial diagnosis of ADLTE is based on concordance for lateral temporal epilepsy in at least two affected family members, intrafamilial recurrence of epilepsy compatible with autosomal dominant inheritance with reduced penetrance, and normal MRI. Outcome is benign with good drug response in most cases.

Mutations causing ADLTE are found in the leucine-rich, glioma-inactivated 1 (LGI1) gene \[[@B5]--[@B7]\]. Overall, LGI1 mutations account for about 50% of ADLTE families, denoting genetic heterogeneity in ADLTE \[[@B3], [@B8]\].

The LGI1 gene encodes a neuronal protein whose predicted structure consists of a signal peptide, four leucine-rich repeats (LRR) in the N-terminal region \[[@B9]\], and seven EPTP (beta-propeller) repeats in the a C-terminal region \[[@B10]\]. Both LRR and beta-propeller domains mediate protein-protein interactions. The Lgi1 protein is secreted in vitro \[[@B11]\] and ADLTE-causing mutations hinder protein secretion, suggesting a loss-of-function effect of mutations \[[@B7]\].

The function of the LGI1 gene and the pattern of Lgi1 protein interactions are not clearly defined. Recent proteomic experiments showed that the Lgi1 protein forms a complex with the postsynaptic proteins PSD-95 and ADAM22 (a disintegrin and metalloprotease 22) \[[@B12]\]. In addition, it was shown that Lgi1 acts as a ligand for the receptor ADAM22 and, as a result of this interaction, potentiates postsynaptic AMPA currents at excitatory synapses, whose malfunction may result in epilepsy \[[@B12]\]. On the other hand, Lgi1 was shown to preferentially interact with ADAM23 and through interaction with this receptor, which is not localized to postsynaptic density, stimulates neurite outgrowth *in vitro* and dendritic arborisation *in vivo* \[[@B13]\]. Finally, analysis of LGI1 knockout and transgenic mice confirmed interaction of Lgi1 with both ADAM22 and ADAM23 \[[@B14]\]. These functional studies suggest that ADAM22 and ADAM23 are plausible candidate genes for ADLTE. In previous studies, we and others excluded ADAM22 as a major causative gene for ADLTE \[[@B15], [@B16]\]. In this work, we assessed the involvement of ADAM23 in ADLTE by linkage analysis of 13 Italian families.

2. Methods {#sec2}
==========

2.1. Family Selection {#sec2.1}
---------------------

We included families followed up at nine Italian Epilepsy Centers. Participating members signed written informed consent, approved by the ethics committee of each center. Personal and family history was obtained from each family member along with neurologic examination. Medical records reporting neurophysiologic, neuroimaging, and history data were collected whenever possible. Seizure types were classified according to the Partial Seizure Symptom Definitions \[[@B17]\]. Clinical description was obtained from each patient and/or one close relative who had witnessed at least one episode. ADLTE was diagnosed when two or more family members had focal seizures with auditory features (whistle, buzzing, ringing, voices, music, loss, or attenuation of sounds) and/or receptive aphasia and there was no suspicion of any other focal epilepsy syndrome. EEG recordings were generally performed according to the international 10--20 system with bipolar and referential montages. Sleep EEGs were also performed whenever possible. All patients underwent 1.5-Tesla MRI.

2.2. Genotype Determination and Linkage Analysis {#sec2.2}
------------------------------------------------

Blood samples were collected from family members. DNA was extracted by standard methods and typed with microsatellite markers, D2S1782, D2S369, and D2S2358, which were chosen for their closeness to the ADAM23 gene ([Figure 1](#fig1){ref-type="fig"}). PCR amplification of microsatellites was performed with fluorescently labelled primers in a thermal cycler (MJ research, Waltham MA, USA). PCR products were fractionated on an ABI3100 apparatus (Applied Biosystems). Linkage analysis was performed by using the SuperLink program of the easyLINKAGE package version 5.02; LOD score values were calculated assuming disease-allele frequency of 0.0001, autosomal dominant inheritance, and penetrance of 0.70. The phenocopy rate was set at 0.0. Family members with only FS who were not obligate carriers were classified as non affected.

3. Results {#sec3}
==========

3.1. General Data and Clinical Findings {#sec3.1}
---------------------------------------

Pedigrees of the thirteen Italian ADLTE families included in the study are shown in [Figure 2](#fig2){ref-type="fig"}. Six of them (I-3, I-4, RAN, CTR, PEL, PRO, ZAN) have already been reported \[[@B3], [@B16], [@B18]\]; the clinical features of the remaining families will be described elsewhere. Inclusion criteria were (1) two or more family members concordant for lateral temporal epilepsy; (2) absence of potentially causative structural brain abnormalities; (3) inheritance pattern compatible with autosomal dominance with reduced penetrance; (4) absence of mutations in the LGI1 gene, as determined by direct sequencing of probands\' DNAs. The number of affected members per family varied from 3 to 8 (mean 4.3). In total, there were 56 patients (34 women, 22 men), 44 living. Of these, 32 (73%) had lateral temporal seizures with auditory (29) or aphasic (3) phenomena. Age at onset ranged between 6 and 43 years (mean 17.6); perinatal and developmental history as well as neurological examination were unremarkable in all subjects; secondarily generalized tonic-clonic seizures occurred in 25 (78%) patients with auditory or aphasic partial seizures, though at low frequency; and the evolution of the condition was relatively benign since seizures were usually well controlled with standard antiepileptic drugs.

3.2. Genetic Findings {#sec3.2}
---------------------

We genotyped our families with three microsatellites (D2S1782, D2S369, and D2S2358) lying within or near the ADAM23 gene ([Figure 1](#fig1){ref-type="fig"}). As shown in [Table 1](#tab1){ref-type="table"}, all three polymorphic markers gave negative or inconclusive results in all families. Particularly, LOD scores \<−2 at Teta 0.0, which definitely excluded linkage, were obtained with one or more markers in nine families. On the other hand, in four families (CN, PL, VD, and ZN) one or more microsatellites gave LOD scores either negative but \>−2 or slightly positive, as was the case of D2S369 in family ZN, which, however, was lower than the expected LOD score (0.30 versus 0.82). Thus, exclusion of linkage in these four families cannot be considered definitive but only probable. Overall, cumulative LOD scores were definitely negative, ranging from −18.96 to −25.86 ([Table 1](#tab1){ref-type="table"}). These results were confirmed by nonparametric multipoint linkage analysis (cumulative HLOD 0.00; data not shown).

4. Discussion {#sec4}
=============

A strategy to identify new ADLTE genes relies on testing candidate genes, such as genes for proteins implicated in the same molecular pathway as Lgi1. Recent experimental evidence showed that Lgi1 preferentially binds to ADAM23, thereby influencing neuronal morphology \[[@B13]\]. Thus, Lgi1 may have a role in the control of neuronal development, which would be impaired in patients carrying LGI1 mutations. This functional model implies that ADAM23 may carry mutations linked to ADLTE at least in part of the families without LGI1 mutations. Our results clearly show that this is not the case and suggest that ADAM23 is not a major gene for ADLTE. This conclusion is strengthened by the methodology we employed, as linkage analysis is more robust than direct sequencing of coding exons, which inevitably overlooks noncoding and large deletion mutations.

An increasing amount of experimental data support interaction between Lgi1 and several ADAM protein family members \[[@B19]\]. Also, the Lgi4 protein has been shown to bind ADAM proteins in the peripheral nervous system \[[@B19]\]. Thus, there seems to be a molecular affinity between LGI and ADAM protein families, which may provide the molecular substrate of a variety of biological functions. However, it is yet to be proved that this molecular pathway actually underlies ADLTE.

In conclusion, our results exclude that ADAM23 has a major role in the aetiology of ADLTE. Whether this gene has more subtle effects on susceptibility to nonfamilial lateral temporal epilepsy remains to be determined.
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![Schematic representation of the ADAM23 gene and surrounding genomic region. The positions of individual gene exons (vertical bars) and microsatellites are indicated.](ERT2011-258365.001){#fig1}

![Pedigrees of ADLTE families. Open squares and circles: unaffected; solid squares and circles: affected; grey square and circles: patients with febrile seizures. Asterisks denote availability of DNAs for linkage analysis.](ERT2011-258365.002){#fig2}

###### 

\(a\) Two-point LOD score obtained at locus D2S1782.

  ----------- ---------------------------- -------------------- ----------- ----------- ------- -------
  Family ID   Expected maximum LOD score   Observed LOD score                                   
  *θ* = 0     *θ* = 0.1                    *θ* = 0.2            *θ* = 0.3   *θ* = 0.4           
                                                                                                
  CN          1.84                         0.00                 0.00        0.00        0.00    0.00
  I-3         1.94                         −2.50                −0.32       −0.11       −0.03   −0.01
  MC          0.37                         0.00                 0.00        0.00        0.00    0.00
  NP          2.55                         −3.01                −0.53       −0.24       −0.10   −0.02
  I-4         1.07                         −2.13                −0.40       −0.14       −0.04   0.00
  DF          0.30                         −0.19                −0.01       0.03        0.03    0.01
  CR          0.30                         −2.41                −0.25       −0.09       −0.04   −0.02
  CT          0.20                         −3.13                −1.03       −0.61       −0.35   −0.15
  FE          0.49                         −2.51                −0.49       −0.27       −0.16   −0.08
  PL          0.67                         0.00                 0.00        0.00        0.00    0.00
  PO          1.28                         −2.62                −1.05       −0.43       −0.15   −0.03
  VD          1.84                         −0.46                −0.28       −0.15       −0.07   −0.02
  ZN          0.82                         0.00                 0.00        0.00        0.00    0.00
  Totals      10.75                        −18.97               −4.37       −2.02       −0.91   −0.31
  ----------- ---------------------------- -------------------- ----------- ----------- ------- -------

###### 

\(b\) Two-point LOD score obtained at locus D2S369.

  ----------- ---------------------------- -------------------- ----------- ----------- ------- -------
  Family ID   Expected maximum LOD score   Observed LOD score                                   
  *θ* = 0     *θ* = 0.1                    *θ* = 0.2            *θ* = 0.3   *θ* = 0.4           
                                                                                                
  CN          1.84                         0.00                 0.00        0.00        0.00    0.00
  I-3         1.94                         −2.50                −0.32       −0.11       −0.03   0.00
  MC          0.37                         −2.83                −0.44       −0.19       −0.08   −0.02
  NP          2.55                         −3.01                −0.53       −0.24       −0.10   −0.02
  I-4         1.07                         −2.30                −0.09       0.03        0.04    0.01
  DF          0.30                         −3.19                −0.69       −0.32       −0.13   −0.03
  CR          0.30                         −2.69                −0.84       −0.51       −0.31   −0.14
  CT          0.20                         −3.25                −1.76       −0.95       −0.48   −0.18
  FE          0.49                         −2.36                −0.32       −0.12       −0.04   −0.01
  PL          0.67                         −0.15                −0.09       −0.05       −0.02   −0.01
  PO          1.28                         −3.42                −1.00       −0.45       −0.17   −0.04
  VD          1.84                         −0.46                −0.28       −0.15       −0.07   −0.02
  ZN          0.82                         0.30                 0.21        0.13        0.06    0.02
  Totals      10.75                        −25.86               −6.16       −2.94       −1.31   −0.43
  ----------- ---------------------------- -------------------- ----------- ----------- ------- -------

###### 

\(c\) Two-point LOD score obtained at locus D2S2358.

  ----------- ---------------------------- -------------------- ----------- ----------- ------- -------
  Family ID   Expected maximum LOD score   Observed LOD score                                   
  *θ* = 0     *θ* = 0.1                    *θ* = 0.2            *θ* = 0.3   *θ* = 0.4           
                                                                                                
  CN          1.84                         −0.96                −0.37       −0.17       −0.07   −0.02
  I-3         1.94                         −2.51                −0.34       −0.12       −0.04   −0.01
  MC          0.37                         −2.83                −0.44       −0.19       −0.08   −0.02
  NP          2.55                         −3.01                −0.53       −0.24       −0.10   −0.02
  I-4         1.07                         −2.47                −0.34       −0.13       −0.05   −0.01
  DF          0.30                         −0.59                −0.39       −0.21       −0.09   −0.02
  CR          0.30                         −0.50                −0.33       −0.21       −0.12   −0.05
  CT          0.20                         −2.99                −0.75       −0.34       −0.13   −0.03
  FE          0.49                         0.40                 0.33        0.24        0.16    0.08
  PL          0.67                         0.00                 0.00        0.00        0.00    0.00
  PO          1.28                         −3.42                −1.00       −0.45       −0.17   −0.04
  VD          1.84                         −0.09                −0.08       −0.06       −0.03   −0.01
  ZN          0.82                         0.00                 0.00        0.00        0.00    0.00
  Totals      10.75                        −18.96               −4.23       −1.88       −0.70   −0.14
  ----------- ---------------------------- -------------------- ----------- ----------- ------- -------
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